Lenalidomide effectively enhances the interaction between E3 ligase CRBN and IKZF1, which leads to the accelerated IKZF1 proteasome-dependent degradation and inhibition of MM proliferation [30–32]. This evidence concerns the gene CRBN and Miyoshi myopathy.